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Abstract
Population ageing is a global phenomenon. People aged 65 years and older comprise
approximately 16% of the population of Europe. The medical management of elderly patients
with inflammatory bowel disease (IBD) is challenging with respect to diagnosis, pharmaceutical
and surgical treatment, and complications. IBD has a late onset in 10%–15% of patients, with the
first flare occurring at 60 to 70 years of age; others suffer from the disease for several decades.
Even though the natural course of the disease in geriatric populations and the diagnostic options
may not differ much from those in younger patients, distinct problems exist in the choice of
medical therapy. Recommended clinical practise has been rapidly evolving towards an
intensified initial treatment in IBD. However, in patients older than 65 years, a gentler approach
should be used, and a combination of immunosuppressive agents should be avoided because of
increased risk of infectious and neoplastic complications. Furthermore, elderly patients with
severe IBD show prolonged, complicated post-operative clinical courses with worse hospital
outcomes, so early surgical intervention for elderly patients is recommended. This article
provides an overview of elderly IBD patient care, including medical and surgical therapeutic
considerations and emphasises the necessity of close collaborations between gastroenterologists
and surgeons.
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There is increasing awareness that clinical aspects of many
gastroenterological diseases, as well as any corresponding
therapeutic approaches, significantly change with ageing.
Patients with inflammatory bowel disease (IBD) that has
presented later in life and patientswho have suffered from IBD
for multiple decades both require notably different clinical
and pharmaceutical management than younger patients.
Elderly IBD patients with co-morbidities are a rapidly growing
population at risk of drug interactions and of fragmentation of
patient care between different medical disciplines. Unfortu-
nately, there is no consensus about the definition of ‘elderly’.
In several publications, the term was arbitrarily assigned to9080706050403020
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Figure 1 Age distribution of patients treated for IBD in a tertiary ca
disease and (B) ulcerative colitis in our centre, demonstrating that 15patient groups between 40 and 75 years of age.1–3 More
recently, anage over 60 years has beenconsideredelderly, but
differentiation of the ‘fit elderly’ from the ‘frail elderly’, as
proposed in a review by Katz and Feldstein,4 may help to
properly select patients for more aggressive therapy.
In our tertiary referral centre, 15.1% of 1202 patients
treated for IBD have been 60 years or older (Fig. 1). The true
incidence of IBD in the elderly is difficult to assess because of
population differences, case definitions, and potential mis-
diagnoses in patients with ischaemic colitis or non-steroidal
anti-inflammatory drug induced colitis. Population-based
studies indicate that approximately 10%–15% of patients are
older than 60 years at diagnosis of IBD, with an equal
distribution between Crohn's disease (CD)5 and ulcerativeAge (Years)
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% of the patients are ≥60 years old.
179IBD in the elderlycolitis (UC).6 Recent annual incidence rates of IBD in patients
≥60 years are 6–12 per 100,000 person-years for CD and 4–17
per 100,000 person-years for UC, according to North American
population-based studies.7,8 The classical view on IBD pro-
posed a bimodal age distribution, with an initial peak between
20 and 30 years and a second peak between 50 and 80 years.
Epidemiological studies fromGermany indicate, however, that
the incidence of UC peaks between the ages of 16 and 25, with
slowly declining incidence rates in the years thereafter.9
Population-based studies from northern France10 and5 Sweden
support these findings.
Unfortunately, few data are available that directly
compare treatment efficacy in younger and older patients.
So far, it is not known whether IBD treatment strategies, such
as induction of remission, may be directly transferable to the
care of elderly patients. Moreover, the safety and effective-
ness of drugs used to treat IBD patients has not been
extensively studied in this patient group. To meet the
challenge of caring for a growing group of elderly patients,
this comprehensive review will provide knowledge specific to
IBD-related treatment-associated complications and limita-
tions in the elderly population.2. Infections in the elderly IBD patients —
steroids potentiate the risk
The elderly have both an increased risk and increased severity
of infection. Possible reasons include differences in epidemi-
ology, increased concomitant morbidity, and immunosenes-
cence, which is a state of age-related immune dysfunction.11
Studies on healthy elderly humans have identified phenotypicOther Seriou
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Figure 2 Frequency of adverse events in patients treated with b
infections in patients treated with biologicals for IBD increases wit
other serious adverse events (cancer, hepatotoxicity and liver fa
patients treatedwith infliximab or adalimumab for IBDwith respect
al.15 (B) Frequency of severe infections and death in patients treat
according to Cottone et al.16and functional changes in the T cell component of adaptive
immunity as an age-related alteration12 leading to infections.
Many elderly with infections present with non-specific clinical
symptoms and non-specific functional decline, which compli-
cates diagnosis and may lead to a life-threatening delay in
diagnosis and therapy.11,13
Several studies confirm that age itself is an independent
risk factor for infectious complications in IBD patients.
Toruner et al.14 demonstrated that the relative risk of
acquiring an opportunistic infection was the greatest in IBD
patients older than 50 years of age (Odds Ratio [OR] 3.0; 95%
Confidence Interval [CI] 1.2–7.2). In another matched case–
control study from the Mayo Clinic, age greater than
60 years was an independent risk factor for adverse events
from biological therapy (HR 1.7; 95% CI 1.1–2.8),15 with
infections as the leading serious adverse events in the older
cohort group (Fig. 2). A large retrospective analysis of IBD
patients treated with infliximab (N=2475) or adalimumab
(N=604) revealed that patients older than 65 years had a
higher rate of severe infections (11% vs. 0.5%) and an
increased mortality (10% vs. 2%) compared to patients who
were treated with other drugs.16 Three out of four deaths
due to infectious complications under therapy with inflix-
imab occur in patients older than 65 years.17
2.1. Immunosuppressive therapy and opportunistic
infections
Immunosuppressive therapy is the leading risk factor for
infectious complications in IBD patients. Immunosuppressive
agentscommonlyusedtotreat IBDpatients includecorticoster-
oids, azathioprine (AZA) or 6-mercaptopurine (6-MP),s
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h age. (A) Frequency of adverse events, severe infections, and
ilure, bleeding peptic ulcer, arthralgia, severe headache) in
to age, according to amatched case–control study by Bhushan et
ed with infliximab or adalimumab for IBD with respect to age,
180 A. Stallmach et al.methotrexate,calcineurin inhibitors (cyclosporin, tacrolimus),
and biologicals such as anti TNF-α agents. Although their mode
of action differs, they all compromise the patient's immune
response to infectious agents. Thus, a wide spectrum of
pathogens, including viral, bacterial, fungal, and protozoan
organisms, has been reported in IBD patients receiving
immunosuppressive therapy.18 The relative risk for opportunis-
tic infections is 3-fold increased (OR 2.9; 95% CI 1.5–5.3) when
corticosteroids, AZA/6-MP, or infliximab is used alone. Pooled
data from controlled clinical trials demonstrate that even
corticosteroid mono-therapy with more than 10 mg predniso-
lone daily, a cumulative dose of 700 mg, or a duration of
treatment of more than two weeks substantially increases the
risk of infectious complications.19 The risk, however, increases
substantially when two or more drugs are used concomitantly
(OR 14.5; 95% CI 4.9–43).14 This observation was confirmed by
two other studies, including the analysis of the TREAT registry,
in which the risk of infectious complications was especially
increased if infliximabwas combinedwith corticosteroids.20,21
Several studies, case reports, and case series indicate
that specific drugs seem to be associated with specific
infections. Corticosteroids block neutrophil extravasation
and monocyte/macrophage activation and may therefore
increase the risk of infections at mucosal surfaces, such as
candidiasis.14 Thiopurines predispose patients to viral infec-
tions, including cytomegalovirus (CMV), herpes simplex virus
(HSV), Varicella zoster virus (VZV), and Epstein–Barr
virus.22–24 Moreover, in a post-marketing surveillance over
10 years, herpetic infections were one of the leading
infectious complications (23%) under infliximab therapy
(data on file, Centocor, PSUR 18, October 2008).
Anti-TNF-α agents increase the risk of acquiring granu-
lomatous infections, such as tuberculosis (TB), by 5- to 30-
fold.25 TB remains one of the most important infectious
diseases worldwide. In Germany, the incidence of tubercu-
losis increases with age, and special caution is therefore
warranted in the elderly.26 Of importance is the fact that
symptoms of fever, weight loss, and night sweats are
mediated by TNF-α and may be therefore masqueraded by
anti-TNF-α agents, leading to atypical presentations.
Strategies to reduce the risk of TB due to TNF-α blockade
emphasise the detection and treatment of latent TB
infection (LTBI). The effectiveness of this strategy has
been documented by the Spanish BIOBADASER registry,
which showed a decline of TB infections by 78%.27 However,
in a study by Sichletidis et al., seven patients treated with
TNF-α antagonists developed active TB despite correctly-
performed chemoprophylaxis.28 Therefore, it is important
to note that even if chemoprophylaxis is performed
correctly in patients with LTBI, they are still at risk of
acquiring TB.
In addition to TB, several endemic and opportunistic
infections in association with immunosuppressive therapy in
IBD patients have been reported in case reports or small
case series. Amongst others, local and systemic candidiasis,
atypical bacterial infections, aspergillosis, coccidioidomy-
cosis, legionellosis, cryptococcal infections, nocardiosis,
toxoplasmosis, Pneumocystis jiroveci pneumonia, dissemi-
nated sporotrichosis, listeriosis, and Histoplasma capsula-
tum infections have been reported.18 Another concern in
IBD patients is the increasing incidence of Clostridium
difficile-associated disease (CDAD).29 Recently Schnee-weiss and colleagues30 showed that the risk of CDAD in IBD
patients treated with corticosteroids was three times
higher than with other immunosuppressive agents (RR 3.4;
95% CI, 1.9–6.1).2.2. Prevention of infection
In light of the increased risk for infection and its associated
mortality in immunosuppressed patients with IBD,31 preven-
tion rather than treatment of infection is fundamental in
these patients. As outlined in a recent review by Viget et al.,
the preventive strategy should be based on risk identifica-
tion, vaccination, and prophylactic treatment.32 Before
initiating therapy, patients have to be evaluated for LTBI
(interferon gamma release assay, chest X-ray, contact with
infectious patients, and travel history), hepatitis B virus
(HBV), human immunodeficiency virus in a high-risk popula-
tion, and history of VZV, HSV and CMV infection. Serum and
urine screening studies for endemic mycoses are recom-
mended. Furthermore, verifying vaccination status and
regularly vaccinating for influenza (annually), HBV, and
pneumococcal disease should be performed. Varicella
vaccine should also be considered for sero-negative patients
but only be administered before immunosuppression has
been started, because varicella vaccine is a (attenuated) live
vaccine. However, the response to vaccination, which
requires intact cell-mediated immunity to drive the humoral
immune response, is clearly diminished in the elderly
population, especially in terms of an impaired response to
influenza infection and/or immunisation to influenza,13 and
further attenuated by immunosuppressive therapy. After
pneumococcal vaccination in one study, for instance, only
45% of the IBD patients on immunosuppressive combination
therapy had an adequate antibody response, compared to
80% of patients not on immunosuppressive therapy.33
Unfortunately, there are no data available concerning
influenza vaccination in elderly IBD patients receiving
immunosuppressive therapy. However, vaccination should
be performed in the elderly because its benefits clearly
outweigh the possible disadvantages. Data on chemoprophy-
laxis for P. jiroveci pneumonia in IBD patients are scarce.
Extrapolating from other groups of immunocompromised
patients, prophylaxis with sulfamethoxazole/trimethoprime
is recommended for patients with a therapeutic regime that
includes calcineurin inhibitors (cyclosporin A or tacrolimus)
or a combination therapy of three immunosuppressant
agents.3. Immunosuppression and malignancies in
older patients — myths and realities
3.1. The risk of lymphoma in elderly IBD patients
Because thiopurines are a well-established, effective main-
tenance therapy for moderate and severe CD34 and for UC,35
the use of azathioprine in CD has constantly increased since
its first application in 1969 to a current cumulative 5-year
probability of more than 50%.36 However, thiopurine-related
adverse events occur in 5% to 40% of patients,37 which leads
to therapy discontinuation in up to 26% of patients.38
181IBD in the elderlyParticular concerns exist about the carcinogenic potential of
thiopurines because early studies revealed a 59-fold risk of
non-Hodgkin's lymphoma (NHL) in renal transplant recipients
receiving AZA.39
The activity and duration of the underlying disease, co-
medication, age, and gender modulate the individual risk of
lymphoma. Whereas patients with rheumatoid arthritis (RA)
have a 2-fold increased risk of lymphoma compared to the
general population,40 most studies have failed to demonstrate
such an increased risk of lymphoma in patientswith IBD.41–43 In
a population-based prospective European study, the standar-
dised incidence ratio (SIR) for lymphoproliferative disorders
was 1.45 (95% CI 0.5 to 3.2) for IBD patients who had never
received thiopurine or anti-TNF-α therapy.44 According to a
large Swedish population-based cohort study that followed
more than 47,000 patients with IBD for up to 40 years, the risk
of lymphoma in UC patients is similar to the general population
(SIR=1.0; 95% CI 0.8 to 1.3), but onlymarginally elevated in CD
(SIR=1.3; 95% CI 1.0 to 1.6).45
In the general population, the incidence of NHL is
approximately 20 in 100,000 person-years, according to the
U.S. Surveillance, Epidemiology, and End Results (SEER)
cancer registry,46 but substantially increases with age. More
than 50% of patients diagnosed with NHL are older than
65 years. The use of thiopurines in IBD markedly increases the
risk of lymphoma compared with the general population
(SIR=4.2; 95% CI 2.1 to 7.5), as demonstrated by a meta-
analysis of six cohort studies.47 The recent prospective
observational cohort study on 19,486 patients with IBD from
the French CESAME group addressed this question and
identified older age (HR 1.06, 95% CI 1.03 to 1.09 per 1-year
increase) and longer duration of IBD (HR=1.04, 95% CI 1.00 to
1.08 per 1-year increase) as themain risk factors of developing
a lymphoproliferative disorder. In a multivariate analysis, the
hazard ratio for malignant lymphoma of patients who received
thiopurines was 5.3 (95% CI 2.2 to 12.6).44 This risk was further
elevated for patients with a continuing combination therapy of
thiopurines and anti-TNF-α therapy (SIR=6.5; 95% CI 3.5 toIBD, Thio
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lymphoproliferative disorders in patients with IBD increases with a
French Study Group CESAME.44 For comparison, the age-dependent m
SEER cancer registry data46 are displayed. IBD: inflammatory bowel11.2). Fig. 3 illustrates the reported effects of IBD, thiopurine
therapy, and age on the incidence rate of malignant
lymphoma.
Because life expectancy and potential benefits of treat-
ment with AZA are greater in younger patients, the potential
benefit of AZA therapy in older CDpatients remains debatable.
This question was assessed by Lewis and co-workers using a
decision-analytic Markov model.48 They showed that the gain
of quality-adjusted life years (QALYs) decreasedwith age upon
initiation of AZA therapy: an assumed 4-year therapy of AZA
would yield an increase in 0.09 QALYs for a 15-year-old patient
but only a b0.01 increase in QALYs for patients older than
55 years. According to this model, starting AZA at an age
greater 65 years would not provide any benefit at all.
Whether a biological therapy further contributes to a
significant risk of a lymphoproliferativedisorder is controversial.
The prospective, observational, multicentre TREAT registry
failed to demonstrate an increased NHL risk for CD patients
treated with infliximab compared to infliximab-naïve CD
patients (RR=0.8; 95% CI=0.22–2.99).49 According to a recent
meta-analysis involving 21,178 patient-years of follow-up,
patients treated with anti-TNF-α agents for CD have a 3-fold
increased risk of NHL.50 Thirteen cases of NHL were observed in
patients treated with biologicals; five of them in patients older
than 60 years. Almost all of the reported patients had current or
prior exposure to thiopurines. When compared with CD patients
taking immunomodulators alone, the rate of NHL for those
exposed to anti-TNF-α agents was not statistically significant.3.2. IBD in the elderly and cancer
Besides the risk of lymphoproliferative disorders, patients
treated for CD have an overall increased risk of cancer,
including of the small intestine (SIR=5.9), testes (SIR=2.4),
kidneys (SIR=2.2), liver (SIR=2.1), skin (SIR=1.9), pancreas
(SIR=1.8), colon (SIR=1.6), endocrine glands (SIR=1.6), and
lung (SIR=1.5).51 Compared to the general population, olderAge (Years
)
>65
50-65
<50n
unosuppressive medication. The mean yearly incidence rates of
ge and ongoing thiopurine therapy, according to data from the
ean yearly incidence rates of malignant lymphoma from the US
disease.
182 A. Stallmach et al.patients diagnosedwith CD at an age N64 years have increased
risk for small intestine carcinoma (SIR=22.5), NHL (SIR=3.9),
pancreatic cancer (SIR=3.3), cancer of the endocrine glands
(SIR = 2.9), kidney cancer (SIR = 2.5), stomach cancer
(SIR=2.0), and lung cancer (SIR=1.8),51 but the same is not
true for UC,52 according to Swedish register data. These
findings emphasise the importance of excluding a malignancy
before beginning a therapy with immunosuppressants or
biologicals in the elderly (see Table 1).
Colorectal cancer (CRC) occurs in 3.7% of UC patients (95%
CI 3.2% to 4.2%, n=54,478) in surveillance programmes and
tertiary care centres.53 Population-based studies, however,
indicate a rather low annual CRC incidence rate of 0.06% to
0.16% in UC patients.54 The risk of colorectal carcinoma in CD
andUC compared to the general population decreaseswith age
of diagnosis, but the relative risk of colon cancer in patients
diagnosed at an age N64 years is still increased in CD
(SIR=2.4),51 emphasising the necessity of endoscopic surveil-
lance in IBD. However, this strategy has to be carefully
adapted to ‘frail elderly’ and to patients older than 80 years
considering individual co-morbidity and life expectancy.
In August 2009, the FDA began requiring stronger warnings
about the possible occurrence of malignancies in patients
receiving anti-TNF-α therapy.55 In the controlled portions of
clinical trials for all indications, the incidence rate of
malignancies, excluding lymphoma and nonmelanoma skin
cancer, in patients receiving infliximab was higher than in the
control groups (520 vs. 110 per 100,000 patient-years),56 but
similar to that of the general population (RR=1.0; 95% CI 0.67
to 1.43).57 Case series and cohort studies report overall
malignancy rates between 0% and 6% in anti-TNF-α-treated
patients, with a predominance of skin, breast, cancer,
colorectal, prostate, and lung cancers,58 but many trials do
not provide an adjusted estimation of expected cases in the
general population. Data from the TREAT registry on CD
patients receiving infliximab comprising 10,796 patient-years
demonstrated a malignancy rate similar to CD patients not
receiving infliximab (RR=0.74; 95% CI 0.49 to 1.12), despite a
higher disease activity and a higher co-medication rate of
prednisone and immunosuppressants in the infliximab group.49
Because the incidences of malignant and premalignant lesions
increase with age, the ECCO evidence-based consensus on the
diagnosis and management of CD is that biologicals are best
avoided in patients with a history of malignancy,59 and that a
strict follow-up of premalignant lesions of the colon, bladder,
and cervix is required in older patients that are underTable 1 Recommended examinations in older patients with
IBD to rule out malignancy before starting immunosuppressants
or biologics.
Procedure
Clinical examination for lymph nodes and palpable masses
Assessment of family history of cancer
Inspection for skin tumours and dermatologist consultation
Chest X-ray to rule out pulmonary and mediastinal masses
Abdominal sonography for solitary tumours
Colonoscopy for malignant and premalignant colorectal lesions
Gynaecologist consultation to rule out breast cancer and high
grade cervical dysplasia (females)
Urologist consultation to rule out prostate cancer (males)consideration of treatment with immunosuppressants and
biologicals.4. Surgical treatment — avoid complications,
maintain function
4.1. Surgery for ulcerative colitis
The principles of surgical therapy in elderly patients do not
differ from those of younger patients with UC. The dogma ‘no
pouch anal anastomosis in those over 50’ established by some
authors in the early 1990s can now be abandoned.60 The gold
standard for surgery is restorative coloproctectomy with ileal
J-pouch anal anastomosis (IPAA). Depending on current
medical treatment and the patient's general condition, IPAA
can be performed in a two- or in a three-step technique, with
total coloproctectomy, IPAA and protective ileostomy (which
is closed at a second visit after 10–12 weeks), or it can be
performed in an approach that includes total coloproctect-
omy, rectum blind closure, and terminal ileostomy, subse-
quent IPAA and protective ileostomy, and finally ileostomy
closure 10–12 weeks later.
Since the introduction of the double-stapled anastomotic
techniques, the functional outcome has improved compared to
the hand-sewn IPAA initially described in 1978 by Parks.61 In the
elderly, stapled IPAA should be preferred to preserve sphincter
function and improve functional outcome. Indeed, the anal
transitional zone (ATZ) plays an important role in maintaining
continence by probing rectal contents and discriminating
between gas, liquid and solid stool.62 The preservation of a
small rectal mucosa cuff, also called a columnar cuff (1.5–
2.0 cm of length in the upper anal canal), and of the ATZ (4–
5 mm above the dentate line) by the double-stapled technique
yields better functional outcomes, with a low risk ofmalignancy
(b1% after 10 years) in the remaining rectal mucosa cuff.62–64
On the other hand, several publications have shown that
mucosectomy does not provide a 100% protection from anal
malignancy after ileal pouch anal surgery.63–66 This aspect
should be considered in the elderly UCpatient. Because of lower
life expectancy, the functional outcome might be more
important than the potential long-term risk of malignancy. For
the same reasons, ileorectal anastomosis, which is mostly
abandoned in young UC patients, still has indications in the
elderly. Another option in patients with impaired continence is
coloproctectomy with permanent Brooke ileostomy.67 This
procedure, which can easily be performed by laparoscopy, is a
valid option for old patients with co-morbidities or with
impaired sphincter function. Especially in the elderly, a well-
functioning ileostomy seems to be preferable over an IPAA with
poor functional outcome and incontinence.
Functional outcome after ileal anal pouch surgery has been
encouraging in the elderly, provided that the patient retains
preoperatively good anal sphincter function.60,68–70 The
double-stapled technique has resulted in a much better
functional outcome compared to hand-sewn anastomosis in
patients over 50 or 55 years.68–71 The incidence of anastomotic
leaks, pouch-related septic complications,4 and ileal anal
pouch failure rates do not differ between younger and older
patients undergoing surgery for UC.60,69,72 In small case
series,73,74 three independent factors of poor surgical outcome
183IBD in the elderlyin older UC patients were defined: male gender, preoperative
albumin level b28 g/L, and the need for urgent surgery.
Delaney et al.60 examined day-time stool frequency,
continence, bowel movements, seepage at night, and quality
of life in patients who underwent IPAA for UC or for familiar
polyposis: there was no major difference in day-time and
night-time stool frequency in the different age groups.
Continence was better during the first 5 years in younger
patients, but this advantage was lost at the 10 year follow-
up. More than 89% of patients older than 65 years at the time
of surgery would undergo the same surgery again, and more
than 93% would recommend it to others. Thus, patient
satisfaction after IPAA is high in elder UC patients and seems
more important than manometric data on sphincter
pressure.4.2. Surgery for complications of crohn's disease
The necessity for surgery seems to be lower in CD patients
with a higher age at the onset of disease, according to a
case–control study of 132 patients75 and a retrospective
cohort study of 552 patients.75 Possible mechanisms
include less small bowel involvement and ileocaecal
disease localisation in the elderly and an age-associated
decline of the innate, humoral, and cell-mediated
immune responses. When surgery for CD complications is
necessary, it is technically not different from that in
younger patients: abscesses should be evacuated, and
stenoses should be resected, or strictureplasty has to be
performed with the dogma of bowel-sparing surgery.
However, surgery for obstruction, fistula, and bleeding
has been associated with an increased risk of postopera-
tive complications in the elderly IBD patient compared to
other indications.76 Although the risk factors for postop-
erative complications increase with age, age itself seems
to be an independent risk factor77 leading to an increased
rate of postoperative complications, increased length of
hospital stay, and increased operating room time in
elderly IBD patients.76 In elderly CD patients, recurrence
after bowel resection was reportedly less common than in
younger patients (43 vs. 64%), but when it occurred, the
time to recurrence was significantly shorter in the elderly
patients (3.7 vs. 5.8 years).78
Several controversial publications exist on postopera-
tive complications in IBD patients treated preoperatively
with steroids,79–81 immunosuppressants,82,83 or biologi-
cals.84–88 Whether perioperative corticosteroid or immu-
nosuppressive treatment in IBD patients increases the
postoperative complication rate is still not clear, espe-
cially in elderly patients, but it appears that in CD
patients more than in UC patients, high-dose corticoste-
roid therapy is worse than any immunosuppressive
treatment. In general, the influence of cognitive function
or other conditions relating to the ability to comply with
treatment should be taken into account. That is essential
before making the diagnosis of corticosteroid-refractory
disease.
In summary, surgical principles in elderly CD or UC
patients do not differ from those in younger ones. In UC,
sphincter function has to be carefully evaluated preoper-
atively if ileal–anal pouch surgery is intended. Hand-sewnanastomosis should be avoided in the elderly in favour of
the double-stapled technique. If continence is impaired,
an ileostomy will be the better alternative. Ileal–rectal
anastomosis still has a place in elderly UC patients.5. Drug interactions and side effects in the
elderly IBD patientThe prevalence of comorbidity from chronic disease increases
with age, which complicates the management of IBD in older
people. More than 50% of older people aged 65 years or more
have at least three comorbidities and a substantial portion
have five or more89 that which often remain unrecognised and
untreated.90 Since drug interactions and polypharmacy are
important complications that accompany comorbidity in IBD,
cardiovascular events, especially heart failure and renal
insufficiency are of special interest.
As mentioned above, anti-TNF-α therapies are highly
effective at reducing disease activity in IBD. As a pro-
inflammatory cytokine, TNF-α is implicated in all stages of
atherosclerosis including endothelial dysfunction, plaque
formation and rupture and promotion of a prothrombotic
state. Therefore, it has been anticipated that TNF-α
blockade may reduce the cardiovascular burden in patients
with IBD. However, clinical studies with anti-TNF-antagonists
have disclosed the potential of aggravating severe heart
failure with excess mortality in patients with heart failure
and worsening of lipid profile.91 Therefore, the use of anti-
TNF-a agents in heart failure (NYHA class III and IV), a co-
morbidity which often seen in the elderly IPB population, is
contraindicated.92
There is evidence to support the use of methotrexate
(MTX) in patients with IBD as a second-line treatment.
However, metabolism and renal or biliary excretion of MTX
may be affected by age and should be considered when using
this drug. Although efficacy and the qualitative adverse
event profile of MTX is equivalent in the young and elderly, a
higher frequency of gastrointestinal and haematological
toxicity occurs in older patients.93 The risk of MTX toxicity
is increased in patients with poor renal function as a result of
drug accumulation.
To assess renal function and MTX metabolite excretion,
serum creatinine is most commonly used for diagnosis
despite it having several limitations in the elderly. Before
starting MTX therapy in older patients, determination of the
glomerular filtration rate and of urinary albumin loss may
help to detect patients at increased renal risk.
Concerning the side effects of immunosuppressive agents
and liability of surgical procedures in the elderly, some
experts favour continuing a low dose of prednisone or
budesonide in the very elderly as maintenance therapy in
inflammatory disorders.22 It should be critically remarked,
that the efficacy of systemic corticosteroids in the mainte-
nance of disease remission in CD has not been clearly
demonstrated. A European study demonstrated that contin-
uous administration of low doses of 6-methylprednisolone
was beneficial in patients who responded initially to
treatment of active disease.23 Nevertheless, long-term use
is more controversial because the increased risk of adverse
events in low doses.
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decreased effectiveness of one medication as a result of
adding another medication. The consumption of medi-
cines rises disproportionately with age: one-third of all
medications are taken by persons above 65 years of age.94
Thus, geriatric patients are treated on average with five
pharmaceuticals,95,96 and 25% of them regularly take
more than six different medications.
The frequency of drug interactions increases with age,
the degree of morbidity, and the number of medicines
prescribed.94,97 There is a 13% risk of drug interactions with
two medications, 38% with four medications and 82% with
seven medications.98 If an individual patient takes eight or
more medications a day, the probability of the occurrence of
drug interactions is close to 100%. Furthermore, the
frequency of adverse drug reactions (ADR) rises exponen-
tially with the number of medications taken.99 Above the age
of 70 years, 56% ADR is registered, and 22% of these are
caused by interactions.100 Patients older than 65 years suffer
from interaction-related ADR 4.5 times more frequently than
patients younger than 65 years.95 The high frequency of
medication interactions in the elderly can be largely
explained by multi-morbidity and multi-medication. Rele-
vant age-specific changes, which contribute to the occur-
rence of drug interactions, are caused by reduced liver and
kidney function.
Interactions of medications may occur through the
influence of the pharmacokinetics and pharmacodynamics,
as well as through pharmaceutical interactions and incom-
patibilities. Interactions pertaining to biotransformation and
excretion are of special significance. Many medications are
metabolised through the cytochrome P-450 isoenzyme. The
following interactions are theoretically conceivable: (i) two
medications are substrates of the same isoenzyme (affinity);
(ii) medications inhibit an isoenzyme (degradation inhibi-
tion); (iii) medications induce an isoenzyme activity (degra-
dation enhancement); (iv) one medication is a substrate and
one is an inhibitor.98
Standard medication for IBD patients includes 5-amino-
salicylic acid (5-ASA), corticosteroids, and thiopurines. When
polymedication is employed for elderly patients, it is
important to examine the medication before the start of
therapy for possible interactions because they may cause
serious side effects in the patients. In the literature,
numerous interactions of 5-aminosalicylic acid, steroids
and azathioprine are described.101 To elucidate this prob-
lem, several particularly important examples are discussed
below.5.1. 5-Aminosalicylic Acid
Patients receiving digoxin for congestive heart failure or
atrial fibrillation should be closely monitored when on
concomitant medication with 5-ASA. In one study, in 2 out
of 10 patients, a 40% reduced digoxin level was determined
8 h after the last dose of 5-ASA (2 g qid), presumably due to a
reduced absorption of digoxin by 5-ASA.101 Further interac-
tions of 5-ASA may occur with the tuberculostatic drug
isoniazid (INH) and the second-line anti-TB drug ethionamide.
5-ASA can reduce or diminish the acetylation of isoniazid,
especially in patients with rapid acetylator phenotypes, andresult in higher blood levels of the drug and thus, to an
increase in toxic reactions. Patients must be monitored for
the occurrence of symptoms of isoniazid toxicity (nausea,
vomiting, and dizziness).102 The simultaneous application of
5-ASA and ethionamide may cause side effects such as
jaundice, hepatitis, nausea, vomiting, diarrhoea, abdominal
pain, and lack of appetite. Regular liver function tests are
essential in patients who receive 5-ASA and ethionamide
because hepatotoxic side effects are more likely to occur,
especially in the presence of diabetes mellitus. For this
reason, ethionamide should be discontinued when serious side
effects occur.
5.2. Thiopurines
AZA and 6-MP are pro-drugs that undergo extensive
metabolism: 6-MP is metabolised by the enzymes thiopurine
S-methyltransferase (TPMT), hypoxanthine guanine phos-
phoribosyltransferase (HPGRT), and xanthine oxidase (XO).
HPGRT catalyses the metabolic steps to produce the
predominantly active metabolites of thiopurine production,
the 6-thioguanine nucleotides (6-TGN), but TPMT competes
with HPGRT for its substrate 6-MP to produce 6-methyl-
mercaptopurine (6-MMP), which is considered responsible for
distinct side-effects of thiopurine therapy.103 XO inactivates
6-MP to 6-thiouric acid, so its inhibition by allopurinol leads
to an increase in efficacy of this immunosuppressive
agent.104 If allopurinol cannot be discontinued in a patient,
the dosage of AZA should be reduced to one-third or one-
quarter of the usual dose. When both agents are adminis-
tered, determination of TPMT enzyme activity prior to
initiating thiopurine therapy and close-meshed control of
full blood count and liver function tests is recommended.103
In patients with congestive heart failure or hypertension, the
combination therapy of an ACE inhibitor and azathioprine
should be avoided because the employment of ACE inhibitors
in patients receiving AZA may lead to leucopenia and
anaemia.105 If the drugs must be prescribed simultaneously,
monitoring for anaemia and leucopenia is necessary.101
Both increasing age and IBD are strong risk factors for the
development of first and recurrent venous thromboembo-
lism.106,107 Thus, therapy with coumarin derivates, such as
phenprocoumon, is often necessary. Decreased INR has been
reported in a few patients following additional dosage of
azathioprine during therapy with phenprocoumon. Possible
mechanisms for these interactions include enhanced phen-
procoumon metabolism via enzyme induction, lowered
resorption of phenprocoumon and increased prothrombin
synthesis. Prothrombin time or INR, as well as the clinical
state of patients, should therefore be strictly controlled, if
AZA is started during oral anticoagulant therapy or discon-
tinued.108 The same applies to warfarin.101
5.3. Methotrexate
Although most co-medications do not significantly affect the
pharmacokinetic profile of MTX, serious toxicity may occur
when it is combined with other antifolates. Similar to MTX,
the inhibitor of Dehydrofolate reductase, sulfonamides and
trimethoprim inhibit pathways to generate tetrahydrofolic acid
that is necessary for synthesis of purines and thymidine. As a
185IBD in the elderlyresult, the concomitant use of trimethoprim–sulfamethoxazole
has been described as a risk factor for developing cytopenia in
patients treated with low-dose MTX for RA.109 Furthermore,
more than 30 case reports attribute the adverse event of MTX-
related cytopenia to the concomitant use of nonsteroidal anti-
inflammatory drugs according to a recent systematic literature
search.110 Several pharmacokinetic and observational studies
suggest an increased risk of MTX interactionwith ASA in high but
not in low doses.110 Since the combination of MTX and
salicylates also increases the frequency of abnormal liver
function tests in a retrospective study on more than 2500
patients with RA this combination should be avoided.111
5.4. Corticosteroids
Metronidazole and ciprofloxacin are the most widely used
antibiotics in clinical practise for the treatment of compli-
cated CD, although their efficacy has not been convincingly
demonstrated in controlled clinical trials. The simultaneous
administration of quinolones and glucocorticoids, especially
in older patients, harbours an increased risk of tendon
ruptures, as demonstrated in post-marketing studies. For
this reason, quinolones should be discontinued if pain,
inflammation, or tendon ruptures occur.
Immunosuppressant therapy in the elderly is associated
with an increased risk of fungal infections, as we pointed out
above. When antifungal therapy is started, it is important to
consider that these agents are effective cytochrome P450
3A4 inhibitors. It is assumed that they increase the plasma
concentrations of glucocorticoids such as budesonide and
methylprednisolone.112 As soon as side effects caused by
steroids occur or intensify, the dose of corticosteroids in
patients treated with antimycotic agents should be reduced.
Regular control of the pituitary–adrenocortical axis is
recommended.
Similar to thiopurines, the combination of corticosteroids
and anticoagulants may be accompanied by an increase or
decrease in the effectiveness of the anticoagulants, and
more frequent control of coagulation parameters is recom-
mended. For patients who undergo surgery, it is important to
know that several case reports have demonstrated an effect
of corticosteroids antagonistic to the effect of muscle
relaxants.113–115 On the other hand, extended simultaneous
administration of both medications increases the risk or the
severity of myopathy and may result in a prolonged muscle-
relaxing effect.116 If muscle relaxation is necessary, the
effectiveness of the muscle relaxants should be checked and
the dosage accordingly adapted. This particularly applies to
patients receiving high-dose corticosteroid therapy. If the
therapy is continued for a longer period of time, a reduced
dose of muscle relaxants should be considered.
6. Conclusions
Immunosuppressive agents carry an increased risk of infec-
tion or malignant complications in elderly IBD patients,
although the degree of this effect has not yet been fully
quantified for each substance. Importantly, concomitant
immunosuppressive therapy increases the risk of side effects
substantially, and it seems that it is the use of corticosteroids
that plays the largest role in the development of serious oropportunistic infections. Steroids, TNF-α antagonists, and
other immunosuppressive medications may mask the symp-
toms of serious infections; therefore, patients on immuno-
suppressive medications should be monitored for early signs
and symptoms of infection. It is important to note that
treatment strategies for complications in elderly IBD
patients consider co-morbidity and the use of other medica-
tions. Clinical suspicion of complications in elderly IBD
patients should prompt careful anamnesis and clinical
investigation, hospitalisation if necessary, and diagnostic
procedures without delay.References
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